Methamphetamine Hydrochloride

Sold as Desoxyn. Every FDA application for this active ingredient: 1 branded and 6 generic.

As of Nov 14, 2026, FDA lists 7 applications for Methamphetamine Hydrochloride (sold as Desoxyn), first approved Dec 31, 1943, with 0 new uses approved and 0 published complete response letters.

First approved: Dec 31, 1943
Applications: 7
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $684K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Methamphetamine HCl	Part D	$684K	+230%	61

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

METHAMPHETAMINE 5 MG TABLET: $5.10 per unitGeneric · -24% in a year

Clinical Trials

52 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary ConditionsMethamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension · Michael Incze	Not applicable	Recruiting	Nov 4, 2026
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During the Withdrawal-Rehabilitation Period of Methamphetamine Use DisorderInsomnia · The First Affiliated Hospital of Zhejiang Chinese Medical University	Not applicable	Not yet recruiting	Oct 28, 2026
Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During PregnancyMethamphetamine Use Disorder, Pregnancy · University of Utah	Not applicable	Not yet recruiting	Sep 30, 2026
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderMethamphetamine Use Disorder · University of Texas Southwestern Medical Center	Phase 2	Recruiting	Sep 17, 2026
Closed-loop tTIS Targeted of the Nac as an Intervention for MUD PatientsAmphetamine Use Disorders · Shanghai Mental Health Center	Not applicable	Not yet recruiting	Sep 3, 2026
Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use DisorderMethamphetamine Use Disorder, Substance Use Disorder · Shanghai Mental Health Center	Not applicable	Active, not recruiting	Aug 20, 2026
Psilocybin for Methamphetamine Use DisorderMethamphetamine Use Disorder · Peter Hendricks	Phase 2	Not yet recruiting	Aug 19, 2026
Psilocybin Therapy for Methamphetamine Use Disorder and HIVMethamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) · Nicky Mehtani, MD, MPH	Phase 2	Recruiting	Aug 11, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Dec 31, 1943	DesoxynNDA 5378	Ajenat Pharms	26	Marketed
Jan 19, 1976	Methamphetamine HydrochlorideANDA 84931	Rexar	0	Discontinued
Feb 25, 2004	Methamphetamine HydrochlorideANDA 40529	Able	0	Discontinued
Apr 21, 2010	Methamphetamine HydrochlorideANDA 91189	Dr Reddys Labs SA	9	Marketed
Nov 17, 2015	Methamphetamine HydrochlorideANDA 203846	Hikma	6	Marketed
—	MethampexANDA 83889	Teva	0	Discontinued
—	Methamphetamine HydrochlorideANDA 86359	Teva	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA